在鼻癌中,EMC2通过调节TFRC抑制铁
Xianghui Chen1, Xiaoyan Wang2, Yuxia Zou3
1Shengli Clinical Medical College of Fujian Medical University, Department of Otolaryngology, Head and Neck Surgery, Fujian Provincial Hospital, Fuzhou 350001, China; Department of Otorhinolaryngology-Head and Neck Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350001, China.
细胞内网膜蛋白质复合体2 (EMC2) 抑制铁亡并促进鼻癌 (NPC) 的进展. 准EMC2-转素受体 (TFRC) 轴为NPC提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 细胞死亡研究 细胞死亡研究
背景情况:
- 鼻癌 (NPC) 是一种表皮性恶性瘤,其分子驱动因素尚未完全理解.
- 作为受调节的细胞死亡途径,铁亡在NPC的背景下还没有得到充分的描述.
研究的目的:
- 为了研究内细胞网膜蛋白复合体2 (EMC2) 在NPC中的作用.
- 阐明EMC2通过哪些分子机制影响NPC中的铁和致癌.
- 评估EMC2作为NPC的潜在生物标志物和治疗目标.
主要方法:
- 使用定量蛋白质组学来识别NPC组织中的失调蛋白质.
- 免疫组织化学被用来评估NPC组织微阵列中的EMC2水平.
- 进行了体外和体内实验,以确定EMC2在铁亡和癌症进展中的功能.
- 蛋白质组学,蛋白酶抑制和泛素检测试验探索了EMC2介导的铁灭路径.
主要成果:
- 在NPC中,EMC2显著上调,与瘤进展和患者生存率差相关.
- EMC2敲击诱导铁亡,降低了NPC细胞活力,迁移和入侵,并增强了西斯的疗效.
- 过度表达EMC2抑制了ferroptosis,促进了恶性病变的进展,并降低了对西斯的敏感性.
- EMC2与转移素受体 (TFRC) 相互作用,促进其降解,从而调节铁亡.
结论:
- EMC2 作为铁亡的抑制剂和NPC进展的促进剂.
- EMC2-TFRC轴代表了一种新的途径,可以调节NPC中的铁亡.
- EMC2具有作为鼻癌的诊断生物标志物和治疗点的潜力.
更多相关视频
09:58Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
Published on: June 27, 2020
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
相关概念视频
Master Transcription Regulators
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Mitogens and the Cell Cycle
Abnormal Proliferation
The Early Endosome: Endocytosis of Transferrin
